Robert C
Chef du service de dermato-oncologie et INSERM U 981, Gustave-Roussy, université Paris-Sud, Le Kremlin-Bicêtre, France.
Ann Dermatol Venereol. 2018 Dec;145 Suppl 7:VIIS40-VIIS46. doi: 10.1016/S0151-9638(18)31288-2.
This year again, several breaking news were published in our field of oncodermatology, especially in the domain of immunotherapy. Many works have reported results on predictive biomarker identification. Concerning melanoma treatment, we were disappointed by the negative results of the phase III trial evaluating the IDO1 inhibitor epacadostat + pembrolizumab versus pembrolizumab. However, many promising preliminary results involving the combinations of anti-PD1 and innate immunity activators have been published. We also have a new anti-BRAF + anti-MEK combination: encorafenib + binimetinib with a good benefit/risk ratio and a particularly favorable safety profile as compared with existing similar combinations. Major steps forward were obtained for locally advanced Merkel cell carcinoma and squamous cell carcinoma with anti-PDL-1 avelumab and anti-PD1 cemiplimab respectively.
今年，我们肿瘤皮肤病学领域又发布了几则重大新闻，尤其是在免疫治疗方面。许多研究报告了预测生物标志物识别的结果。关于黑色素瘤治疗，评估吲哚胺2,3-双加氧酶1（IDO1）抑制剂依帕司他+派姆单抗与派姆单抗对比的III期试验结果为阴性，这让我们感到失望。然而，许多涉及抗程序性死亡蛋白1（anti-PD1）与先天免疫激活剂联合使用的有前景的初步结果已经发表。我们还有一种新的抗BRAF+抗MEK联合用药：恩考芬尼+比美替尼，与现有的类似联合用药相比，其获益/风险比良好，安全性尤其有利。局部晚期默克尔细胞癌和鳞状细胞癌分别在使用抗程序性死亡配体1（PDL-1）阿维鲁单抗和抗PD1西米普利单抗方面取得了重大进展。
